GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIKLY) » Definitions » Cyclically Adjusted Price-to-FCF

Grifols (Grifols) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Grifols Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Grifols Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Grifols's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Cyclically Adjusted Price-to-FCF Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.14 42.21 - - -

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Grifols's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Grifols's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Grifols's Cyclically Adjusted Price-to-FCF falls into.



Grifols Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Grifols's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Grifols's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/121.2698*121.2698
=0.000

Current CPI (Dec. 2023) = 121.2698.

Grifols Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201306 0.146 100.994 0.175
201309 0.036 100.597 0.043
201312 0.169 101.306 0.202
201403 0.075 100.139 0.091
201406 0.179 101.081 0.215
201409 0.178 100.441 0.215
201412 0.219 100.251 0.265
201503 -0.256 99.474 -0.312
201506 0.339 101.138 0.406
201509 -0.136 99.559 -0.166
201512 0.191 100.268 0.231
201603 -0.003 98.638 -0.004
201606 0.036 100.333 0.044
201609 0.109 99.737 0.133
201612 0.068 101.842 0.081
201703 0.062 100.896 0.075
201706 0.126 101.848 0.150
201709 0.108 101.524 0.129
201712 0.139 102.975 0.164
201803 0.030 102.122 0.036
201806 0.073 104.165 0.085
201809 0.075 103.818 0.088
201812 0.182 104.193 0.212
201903 -0.209 103.488 -0.245
201906 0.174 104.612 0.202
201909 0.097 103.905 0.113
201912 0.058 105.015 0.067
202003 0.015 103.469 0.018
202006 0.299 104.254 0.348
202009 0.200 103.521 0.234
202012 0.138 104.456 0.160
202103 0.103 104.857 0.119
202106 0.078 107.102 0.088
202112 0.000 111.298 0.000
202206 0.000 118.044 0.000
202209 0.000 117.221 0.000
202212 0.000 117.650 0.000
202306 0.000 120.278 0.000
202309 0.000 121.343 0.000
202312 0.000 121.270 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Grifols  (OTCPK:GIKLY) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Grifols Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Grifols's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols (Grifols) Business Description

Industry
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.